Fulgent Genetics, Inc. (FLGT)
Nasdaq · Services-Medical Laboratories · Services · CIK 1674930 · fiscal year ends in Dec
Closing price $21.66 on 29 Oct 2026; 52-week range $13.79 to $30.85.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $323.9M
- Revenue growth
- 6.8%
- Net income, last twelve months
- -$84.4M
- Earnings per share
- -$2.82
- Gross margin
- 35.6%
- Operating margin
- -37.7%
- Net margin
- -26.0%
- Free cash flow
- -$103.8M
- Return on equity
- -8.4%
- Market value
- $596.1M
- Cash
- $26.3M
- Debt
- $1.5M
- Debt to equity
- 0.00
- Shares outstanding
- 27.5M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $322.7M | -$91.1M | -$60.5M | -$1.97 | -$124.2M | 10-K filed 27 Feb 2026 |
| FY2024 | 31 Dec 2024 | $283.5M | -$73.9M | -$42.7M | -$1.41 | -$19.3M | 10-K filed 28 Feb 2025 |
| FY2023 | 31 Dec 2023 | $289.2M | -$195.5M | -$167.8M | -$5.63 | $4.8M | 10-K filed 28 Feb 2024 |
| FY2022 | 31 Dec 2022 | $619.0M | $178.5M | $143.4M | $4.63 | $234.7M | 10-K filed 28 Feb 2023 |
| FY2021 | 31 Dec 2021 | $992.6M | $676.0M | $507.4M | $16.38 | $514.8M | 10-K filed 28 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $85.4M | -$29.5M | -$1.05 |
| Q1 FY2026 | 31 Mar 2026 | $71.1M | -$24.8M | -$0.80 |
| Q4 FY2025 | 31 Dec 2025 | $83.3M | -$23.4M | -$0.76 |
| Q3 FY2025 | 30 Sep 2025 | $84.1M | -$6.6M | -$0.21 |
| Q2 FY2025 | 30 Jun 2025 | $81.8M | -$19.0M | -$0.62 |
| Q1 FY2025 | 31 Mar 2025 | $73.5M | -$11.5M | -$0.37 |
| Q4 FY2024 | 31 Dec 2024 | $76.2M | -$5.9M | -$0.19 |
| Q3 FY2024 | 30 Sep 2024 | $71.7M | -$14.6M | -$0.48 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Laboratory Services | $322.2M | 99.9% |
| Therapeutic Development | $447.0K | 0.1% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $296.6M | 91.9% |
| Other countries | $13.2M | 4.1% |
| China | $12.9M | 4.0% |
Company events
The newest 8-K filings of 77 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 30 Jul 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 2 Jun 2026 | 8-K | Other events | 8.01, 9.01 |
| 21 May 2026 | 8-K | Other events | 8.01, 9.01 |
| 14 May 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 1 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 17 Mar 2026 | 8-K | Deal completed, Material agreement, Investor update | 1.01, 2.01, 7.01, 9.01 |
| 27 Feb 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 22 Dec 2025 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
| 7 Nov 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 20 Oct 2025 | 8-K | Other events | 8.01, 9.01 |
| 1 Aug 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 15 May 2025 | 8-K | Shareholder vote | 5.07 |
Every filing
The newest filings with the SEC of 182 held.
| Filed | Form | Period |
|---|---|---|
| 30 Jul 2026 | 10-Q | 30 Jun 2026 |
| 30 Jul 2026 | 8-K | 30 Jul 2026 |
| 2 Jun 2026 | 8-K | 1 Jun 2026 |
| 21 May 2026 | 8-K | 21 May 2026 |
| 14 May 2026 | S-8 | – |
| 14 May 2026 | 8-K | 14 May 2026 |
| 1 May 2026 | 10-Q | 31 Mar 2026 |
| 1 May 2026 | 8-K | 1 May 2026 |
| 31 Mar 2026 | ARS | 31 Dec 2025 |
| 31 Mar 2026 | DEFA14A | – |
| 31 Mar 2026 | DEF 14A | 31 Mar 2026 |
| 17 Mar 2026 | 8-K | 17 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 2 Sep 2026 | Gao Hanlin, Chief Scientific Officer | Sale outside a trading plan | 1,673 | $19.66 | $32.9K | 986,117 | 3 Sep 2026 |
| 2 Sep 2026 | Xie Jian, President and COO | Sale outside a trading plan | 2,127 | $19.66 | $41.8K | 359,924 | 3 Sep 2026 |
| 27 Aug 2026 | Xie Jian, President and COO | Sale outside a trading plan | 1,193 | $19.91 | $23.7K | 362,051 | 28 Aug 2026 |
| 27 Aug 2026 | Gao Hanlin, Chief Scientific Officer | Sale outside a trading plan | 939 | $19.91 | $18.7K | 987,790 | 28 Aug 2026 |
| 2 Jun 2026 | Xie Jian, President and COO | Sale outside a trading plan | 2,146 | $17.89 | $38.4K | 367,605 | 3 Jun 2026 |
| 2 Jun 2026 | Gao Hanlin, Chief Scientific Officer | Sale outside a trading plan | 1,688 | $17.89 | $30.2K | 990,374 | 3 Jun 2026 |
| 27 May 2026 | Xie Jian, President and COO | Sale outside a trading plan | 1,201 | $17.60 | $21.1K | 369,751 | 28 May 2026 |
| 27 May 2026 | Gao Hanlin, Chief Scientific Officer | Sale outside a trading plan | 945 | $17.60 | $16.6K | 992,062 | 28 May 2026 |
| 2 Dec 2025 | Xie Jian, President and COO | Sale outside a trading plan | 1,140 | $28.33 | $32.3K | 336,749 | 3 Dec 2025 |
| 2 Dec 2025 | Gao Hanlin, Chief Scientific Officer | Sale outside a trading plan | 1,075 | $28.33 | $30.5K | 952,890 | 3 Dec 2025 |
| 28 Nov 2025 | Xie Jian, President and COO | Sale outside a trading plan | 1,198 | $29.57 | $35.4K | 337,889 | 1 Dec 2025 |
| 28 Nov 2025 | Gao Hanlin, Chief Scientific Officer | Sale outside a trading plan | 943 | $29.57 | $27.9K | 953,965 | 1 Dec 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 2 Sep 2026 | Gao Hanlin, Officer | 1,673 | $32.9K | 2 Sep 2026 |
| 2 Sep 2026 | Xie Jian, Officer | 2,127 | $41.8K | 2 Sep 2026 |
| 27 Aug 2026 | Gao Hanlin, Officer | 939 | $18.7K | 27 Aug 2026 |
| 27 Aug 2026 | Xie Jian, Officer | 1,193 | $23.7K | 27 Aug 2026 |
| 2 Jun 2026 | Xie Jian, Officer | 2,146 | $38.4K | 2 Jun 2026 |
| 1 Dec 2025 | Gao Hanlin, Officer | 1,070 | $30.5K | 2 Dec 2025 |
| 1 Dec 2025 | Xie Jian, Officer | 1,135 | $32.4K | 2 Dec 2025 |
| 26 Nov 2025 | Gao Hanlin, Officer | 943 | $28.4K | 28 Nov 2025 |
| 26 Nov 2025 | Xie Jian, Officer | 1,198 | $36.1K | 28 Nov 2025 |
| 24 Nov 2025 | Gao Hanlin, Officer | 535 | $16.3K | 24 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 May 2026 | Ming Hsieh | 13D amended | 32.26% | 8.9M |
| 31 Mar 2026 | Ming Hsieh | 13D amended | 30.74% | 8.9M |
| 4 Feb 2026 | Integrated Core Strategies (US) LLC | 13G amended | 3% | 939.4K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.1M | -4.71% | 7.41 |
| 30 Sep 2026 | 2.2M | -3.44% | 7.18 |
| 15 Sep 2026 | 2.3M | -2.12% | 6.71 |
| 31 Aug 2026 | 2.4M | -7.33% | 9.97 |
| 14 Aug 2026 | 2.6M | -0.37% | 9.32 |
| 31 Jul 2026 | 2.6M | -6.85% | 8 |
| 15 Jul 2026 | 2.8M | +4.82% | 11.43 |
| 30 Jun 2026 | 2.6M | -3.7% | 7.9 |
Funds that hold it
From each fund's latest Form 13F.
177 funds held it at 30 Jun 2026: 58 added and 55 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 2,286,669 | $46.9M | -487,850 |
| Acadian Asset Management LLC | 1,017,913 | $20.9M | -216,038 |
| Vanguard Capital Management LLC | 789,498 | $16.2M | -90,652 |
| Jacobs Levy Equity Management, Inc. | 782,116 | $16.0M | +425,757 |
| JPMorgan Chase & Co. | 756,558 | $15.5M | +296,195 |
| Diametric Capital, LP | 697,784 | $14.3M | +336,738 |
| Ameriprise Financial Inc. | 670,084 | $13.8M | +106,709 |
| Dimensional Fund Advisors LP | 625,355 | $12.8M | -46,309 |
| Geode Capital Management, LLC | 521,014 | $10.7M | -63,193 |
| State Street Corp. | 498,673 | $10.2M | -30,726 |
Peers
Companies in the same industry.
- Natera, Inc. (NTRA): revenue $2.7B, market value $62.6B
- Labcorp Holdings Inc. (LH): revenue $14.3B, market value $29.8B
- Quest Diagnostics Inc. (DGX): revenue $11.8B, market value $27.8B
- Guardant Health, Inc. (GH): revenue $1.2B, market value $24.8B
- Caris Life Sciences, Inc. (CAI): revenue $989.6M, market value $10.2B
- Grail, Inc. (GRAL): revenue $165.3M, market value $7.1B
- RadNet, Inc. (RDNT): revenue $2.3B, market value $5.8B
- Veracyte, Inc. (VCYT): revenue $561.9M, market value $4.2B
- CareDx, Inc. (CDNA): revenue $497.4M, market value $3.8B
- Fortrea Holdings Inc. (FTRE): revenue $2.7B, market value $2.2B